Saturday - May 16, 2026
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With CtDNA-Guided Treatment
May 16, 2026
SOUTH SAN FRANCISCO, California, May 16 -- Genentech, a member of Roche Group, issued the following news release:

* * *

FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

* First approved ctDNA MRD-guided therapy reinforcing Genentech's commitment to innovation and practice-changing precision medicine

* New treatment approach enables healthcare professionals to tailor treatment w . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products